Molecular and immune biomarker testing in squamous-cell lung cancer: Effect of current and future therapies and technologies

Authors

Jeffrey D. Bradley, Washington University School of Medicine in St. Louis
et al

Journal

Clinical lung cancer

Publication Date

2018

Volume

19

Issue

4

Inclusive Pages

331-339

Document Type

Open Access Publication

DOI

10.1016/j.cllc.2018.03.014

Rights and Permissions

Hirsch FR, Kerr KM, Bunn PA Jr, Kim ES, Obasaju C, Pérol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N. Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. Clin Lung Cancer. 2018 Jul;19(4):331-339. doi: 10.1016/j.cllc.2018.03.014. ª2018 The Authors. Published by Elsevier Inc. This is an open access articleunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).https://doi.org/10.1016/j.cllc.2018.03.014

Recommended Citation

Bradley, Jeffrey D. and et al, "Molecular and immune biomarker testing in squamous-cell lung cancer: Effect of current and future therapies and technologies." Clinical lung cancer. 19, 4. 331-339. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7757